John Jumper

Director — Google DeepMind

Profile

John Jumper led the team that solved one of the longest-standing open problems in biology — predicting how a protein will fold from its amino acid sequence. For fifty years this was the holy grail of computational biochemistry. In 2020, AlphaFold 2 effectively closed the question. In 2024, Jumper shared the Nobel Prize in Chemistry with Demis Hassabis and David Baker for it.

His path is unusual for an AI researcher. Born in Little Rock, Arkansas, he studied physics and math at Vanderbilt, picked up an MPhil in theoretical condensed matter physics at Cambridge, then did a PhD in chemistry at the University of Chicago focused on machine learning for protein folding. In between, he spent three years at D.E. Shaw Research building molecular dynamics simulations — the kind of deep physics-and-systems background that turned out to be exactly right for the problem. He joined Google DeepMind in 2017 as a research scientist and was promoted by Hassabis in 2018 to lead AlphaFold 2. He has been a director at DeepMind since 2023.

What makes Jumper interesting to developers learning AI isn’t just the result — it’s the architecture. AlphaFold 2 isn’t a single model; the Nature paper describes 32 distinct algorithmic components stitched together with strong inductive biases from structural biology. It’s the canonical example of what happens when deep learning is fused with real domain knowledge instead of dropped on top of it. AlphaFold 3, released in 2024, swapped the architecture for a diffusion-based model and extended predictions to protein-ligand, protein-nucleic-acid, and antibody-antigen complexes — the building blocks of drug discovery.

The downstream impact is the part that matters. The AlphaFold Protein Structure Database, built with EMBL-EBI, holds predicted structures for over 200 million proteins — basically every protein known to science — and has been used by more than three million researchers across 190 countries. AlphaFold 3 powers Isomorphic Labs, the DeepMind drug-discovery spin-out now in pharma partnerships worth billions. This is one of the few cases where you can point at AI and say: it is, right now, helping cure disease.